News
Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.
15h
Zacks Investment Research on MSNJNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?Both Johnson & Johnson JNJ and Merck MRK are leading U.S. healthcare conglomerates — blue-chip pharmaceutical companies with ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results